Bristol-Myers ends development agreement with Merck

Article

Bristol-Myers Squibb and Merck have agreed to end their collaborative development of the investigational oral diabetes drug Pargluva (muraglitazar). Under the termination agreement, all rights to muraglitazar were returned to Bristol-Myers effective Dec. 21, 2005. The agreement also returns to Bristol-Myers the rights to a backup compound to muraglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor. Bristol-Myers did indicate that it would continue discussions with the FDA about the drug.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
Related Content
Collaborative, Pharmacist-Led Approach Crucial in Polypharmacy

Collaborative, Pharmacist-Led Approach Crucial in Polypharmacy

Brian Nowosielski
July 18th 2025
Article

Emphasizing the pharmacist’s essential role, researchers explored the causes, consequences, and clinical implications of polypharmacy.

The Evolving Landscape of Insulin Delivery in Diabetes Management

The Evolving Landscape of Insulin Delivery in Diabetes Management

Brian Nowosielski;Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
July 17th 2025
Podcast

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

FDA Approves GSK’s Shingles Vaccine in Prefilled Syringe

FDA Approves GSK’s Shingles Vaccine in Prefilled Syringe

Killian Meara
July 18th 2025
Article

The new presentation of Shingrix will allow for easier administration.

Wicked Good Cardiometabolic Chat: Semaglutide’s Expanding Role in Chronic Disease

Wicked Good Cardiometabolic Chat: Semaglutide’s Expanding Role in Chronic Disease

Killian Meara;Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP;Hailey Choi, PharmD, BCACP, CDCES
July 15th 2025
Podcast

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Brian Nowosielski
July 17th 2025
Article

Researchers conducted a review of pharmacist interventions and their ability to impact the outcomes of patients with COPD.

Bristol Myers Squibb, Pfizer to Sell Eliquis Direct to Patients

Bristol Myers Squibb, Pfizer to Sell Eliquis Direct to Patients

Brian Nowosielski
July 17th 2025
Article

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

© 2025 MJH Life Sciences

All rights reserved.